Sweet's syndrome during the treatment of acute promyelocytic leukemia with all-trans retinoic acid.

22Citations
Citations of this article
24Readers
Mendeley users who have this article in their library.

Abstract

All-trans retinoic acid (ATRA) is the standard induction treatment for acute promyelocytic leukemia (APL). Quite many ATRA-related side effects, including retinoic acid syndrome, were reported. So far, it has rarely been reported that Sweet's syndrome, characterized by fever, neutrophilia, painful erythematous cutaneous plaques, dense dermal infiltrates of mature neutrophils and rapid response to steroid therapy, is associated with ATRA. In the case that Sweet's syndrome associated with ATRA is found, physicians will have to face a great challenge over the possibility of infectious conditions. We present here a case of Sweet's syndrome associated with ATRA. A 35-year-old female with APL developed fever, painful erythematous cutaneous plaques on both cheeks, right wrist and both shins during induction chemotherapy with ATRA. A skin biopsy revealed a dense dermal infiltrate, consisting of mature neutrophils without vasculitis or cutaneous immunoglobulin deposits, which is compatible with Sweet's syndrome. Oral prednisone was administered and the lesions started to improve within 48 hours.

Cite

CITATION STYLE

APA

Park, C. J., Bae, Y. D., Choi, J. Y., Heo, P. S., Lee, K. S., Park, Y. S., & Lee, J. A. (2001). Sweet’s syndrome during the treatment of acute promyelocytic leukemia with all-trans retinoic acid. The Korean Journal of Internal Medicine, 16(3), 218–221. https://doi.org/10.3904/kjim.2001.16.3.218

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free